XML 46 R33.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segments of Business (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2018
Segment Reporting [Abstract] |
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals | Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
| Quarter Ended June 30,
(In millions) | 2018 |  | 2017
Revenues |  |  |
U.S. Pharmaceutical and Specialty Solutions (1) | $ | 40,977 |  |  | $ | 40,282 |
European Pharmaceutical Solutions (2) | 6,935 |  |  | 6,382 |
Medical-Surgical Solutions (3) | 1,703 |  |  | 1,533 |
Other | 2,992 |  |  | 2,854 |
Total Revenues | $ | 52,607 |  |  | $ | 51,051 |
Operating profit |  |  |
U.S. Pharmaceutical and Specialty Solutions (4) | $ | 543 |  |  | $ | 475 |
European Pharmaceutical Solutions (5) | (560 | ) |  | 35 |
Medical-Surgical Solutions | 93 |  |  | 108 |
Other (6) | 114 |  |  | 17 |
Total | 190 |  |  | 635 |
Corporate Expenses, Net | (123 | ) |  | (109 | )
Interest Expense | (61 | ) |  | (68 | )
Income from Continuing Operations Before Income Taxes | $ | 6 |  |  | $ | 458 |
Revenues, net by geographic area |  |  |
United States | $ | 42,890 |  |  | $ | 42,093 |
Foreign | 9,717 |  |  | 8,958 |
Total Revenues | $ | 52,607 |  |  | $ | 51,051 |
(1) | Revenues derived from services represent less than 1% of this segment’s total revenues.
(2) | Revenues derived from services represent less than 10% of this segment’s total revenues.
(3) | Revenues derived from services represent less than 1% of this segment’s total revenues.
(4) | Our U.S. Pharmaceutical and Specialty Solutions segment operating profit for the first quarters of 2019 and 2018 includes $21 million in pre-tax credits and $26 million in pre-tax charges related to our last-in, first-out (“LIFO”) method of accounting for inventories. The LIFO inventory credit in the first quarter of 2019 was primarily due to lower full year expectations for net price increases compared to the same period a year ago. Operating profit for the first quarter of 2019 also includes $35 million of cash receipts for our share of antitrust legal settlements.
(5) | European Pharmaceutical Solutions segment’s operating profit for the first quarter of 2019 includes non-cash goodwill impairment charges (pre-tax and after-tax) of $570 million.
(6) | The first quarter of 2019 operating profit for Other includes pre-tax restructuring charges of $38 million (pre-tax and after-tax) primarily associated with the closure of retail pharmacy stores within our Canadian business. Operating profit for the first quarter of 2019 also includes a pre-tax gain from escrow settlement of $97 million representing certain indemnity and other claims related to our 2017 third quarter acquisition of Rexall Health. Operating profit for the first quarter of 2018 includes a pre-tax gain of $37 million (after-tax gain of $22 million) upon the finalization of net working capital and other adjustments related to the contribution of the majority of our Core MTS Business to Change Healthcare in the fourth quarter of 2017.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration